A nephrogenic mechanism underlies dexmedetomidine-induced polyuria. A case report

Rev Esp Anestesiol Reanim (Engl Ed). 2024 Apr;71(4):332-338. doi: 10.1016/j.redare.2022.10.012. Epub 2023 Sep 16.

Abstract

Dexmedetomidine's α-adrenoreceptor agonism has been gaining popularity in the anesthetic room as a sedative-hypnotic and analgesic agent, and with extensive perioperative use rising concern about side effects is necessary. Bradycardia and hypotension are common adverse effects, but there are also several reports of excessive urine output, possibly due to vasopressin secretion and permeability of collecting ducts. Polyuria usually resolves with discontinuation of the drug, and significant morbidity has not been reported. Early identification, removal of the agent, and treatment are imperative to minimize complications - mainly natremia and neurological symptoms. This case report describes a dexmedetomidine-related polyuric syndrome during opioid-free general anesthesia for major head and neck surgery. A nephrogenic mechanism for the clinical effect is proposed and reinforced by analytical data obtained. An intra-operative polyuria approach is also delineated.

Keywords: Dexmedetomidina; Dexmedetomidine; Farmacología; Pharmacology; Poliuria; Polyuria.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic alpha-2 Receptor Agonists / adverse effects
  • Adrenergic alpha-2 Receptor Agonists / therapeutic use
  • Anesthesia, General
  • Dexmedetomidine* / adverse effects
  • Dexmedetomidine* / therapeutic use
  • Humans
  • Hypnotics and Sedatives / adverse effects
  • Intraoperative Complications / chemically induced
  • Male
  • Middle Aged
  • Polyuria* / chemically induced

Substances

  • Dexmedetomidine
  • Adrenergic alpha-2 Receptor Agonists
  • Hypnotics and Sedatives